World Bank’s IFC and HDFC AMC Propel Molbio Diagnostics with Rs 281 Crore IPO Anchor Investment.

The recent return of the International Finance Corporation (IFC) as an anchor investor in India’s IPO market marks a significant development for Molbio Diagnostics, a Goa-based leader in point-of-care diagnostics. With an investment of Rs 20 crore, IFC joins other notable institutional backers, including Temasek and Motilal Oswal Private Equity, validating Molbio’s status as Goa’s first unicorn. The company successfully raised Rs 281 crore from various anchor investors ahead of its IPO, which is scheduled to open for subscription on August 10 and close on August 12. The participation of the IFC, which last engaged in the Indian IPO space in 2021, signals renewed institutional interest in the diagnostics sector and enhances Molbio’s market credibility.

A secondary sale ahead of the IPO saw institutional investors acquiring shares worth Rs 160 crore, with participation from several alternative investment funds and notable entities such as Kotak Mahindra Life Insurance and Susquehanna Asia Technology. This robust pre-IPO activity points to a healthy institutional appetite for equity in Molbio, suggesting expectations of strong future performance. Offering insights into the company’s financial resilience, brokerages like BP Wealth and Ventura Securities have issued positive subscription recommendations, underscoring Molbio’s impressive projected growth metrics. SBI Securities anticipates a compound annual growth rate of 31.5% in revenue from FY24 to FY26, along with solid EBITDA and adjusted profit growth.

The IPO is valued at Rs 940 crore, with a pricing strategy that reflects a reasonable valuation based on projected future earnings. At a FY26 price-to-earnings ratio of 56.5 and an EV/EBITDA of 28.5, the valuation appears aligned with Molbio’s growth trajectory and profitability ratios within the diagnostics ecosystem. Furthermore, the IPO proceeds will primarily support growth initiatives, including R&D infrastructure development and equipment acquisition for expanding production capabilities. Given the favorable market sentiment and institutional backing, investors should monitor this IPO closely as potential returns could be supported by the accelerating demand for molecular diagnostics and the company’s strategic market expansions.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)